Natus Medical Incorporated (NASDAQ:BABY) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

0
Natus Medical Incorporated (NASDAQ:BABY) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Natus Medical Incorporated (NASDAQ:BABY) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 of Form 8-K. All other information set forth in the Original Form 8-K is otherwise unchanged and is incorporated herein by reference.

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On February 13, 2019, Natus Medical Incorporated (the “Company”) filed a Current Report on Form 8-K announcing the appointment of Alice D. Schroeder and Thomas J. Sullivan to the Company’s board of directors (the “Board”) on February 11, 2019 and that the Board had not made any determinations regarding Board committee assignments for Ms. Schroeder or Mr. Sullivan at that time. On March 12, 2019, the Board appointed Ms. Schroeder as the chairperson of its Nominating and Governance Committee and as a member of the Audit Committee, the Compensation Committee and the Compliance and Quality Committee. The Board also appointed Mr. Sullivan as the chairperson of the Compensation Committee and as a member of the Audit Committee and the Nominating and Governance Committee.

About Natus Medical Incorporated (NASDAQ:BABY)

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The Company’s segment is neurology and newborn care product families. Its product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories. It is organized into two strategic business units: Neurology and Newborn Care.